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ABSTRACT 
 
Background: To evaluate the effects of topically applied axitinib, a tyrosine kinase 
inhibitor, in an experimental model of corneal neovascularization (CNV).  
Methods: Forty-eight New Zealand rabbits were used. CNV was induced by placing 
5 silk sutures in the upper cornea of one eye per rabbit. Rabbits were randomized 
into four groups (12 rabbits each): 0.9% saline (control group), 0.02 mg/ml axitinib, 
0.35 mg/ml axitinib and 0.5 mg/ml axitinib groups. All treatments were administered 
three times daily for 14 days. Photographs were taken using a slit lamp on day 7 and 
14. The area of neovascularization was measured in mm2, as the percentage of total 
corneal area and as the percentage of corneal surface covered by sutures.  
Results: On day 14, the CNV area in the control group (31.50 ± 7.47 mm2; 115.00  
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± 22.55% of the corneal surface covered by sutures) was larger than that in the 
0.02 mg/ml axitinib group (19.20 ± 8.92 mm2; 73.89 ± 34.98%), the 0.35 mg/ml 
axitinib group (8.83 ± 3.92 mm2; 31.90 ± 13.59%) and the 0.5 mg/ml axitinib 
group (5.12 ± 3.97 mm2; 18.38 ± 13.65%). Compared with saline, CNV was 
inhibited 39.04% by 0.02 mg/ml axitinib, 71.96% by 0.35 mg/ml axitinib and 
84.73% by 0.5 mg/ml axitinib.  
Conclusion: Topical administration of the three axitinib concentrations inhibited 
CNV in rabbits, blocking both VEGF and platelet-derived growth factor pathways. 
Axitinib at 0.5 mg/ml induced profound inhibition of corneal angiogenesis.  
 
Keywords: Axitinib, Tyrosine kinase inhibitor, Corneal neovascularization, Cornea, 
angiogenesis  
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INTRODUCTION 
 
Corneal neovascularization (CNV) is a common consequence of several 
inflammatory, infectious and traumatic corneal diseases.1 In addition, 
neovascularization introduces circulating immune cells, reducing the immune 
privilege of the cornea and subsequently compromising the survival of corneal 
transplant grafts.2 
VEGF is commonly considered the most prominent angiogenic factor. Among 
members of the VEGF family, VEGF-A is considered the major factor involved in 
hemangiogenesis, receiving the greatest attention as a mediator of pathologic 
neovascularization. VEGF-A and its tyrosine kinase receptors (VEGFR-1 and VEGFR-
2) are involved in many aspects of the angiogenic process: vascular permeability, 
survival, migration and proliferation of endothelial cells and capillary tube 
formation.3,4 On the other hand, VEGF-C and VEGF-D bind to the VEGFR-3 receptor 
with a strong capacity to induce lymphangiogenesis.5 
Vascular endothelial cells produce PDGF-B and surrounding mural cells, such 
as pericytes and vascular smooth muscle cells, express its receptor (PDGFR-β). PDGF 
induces the recruitment of pericytes and allows the maturation of neoformed 
vessels.6 Blood vessel maturation can be characterized by a decreased sensitivity to 
anti-VEGF therapy. Therefore, removal of pericytes from unwanted blood vessels 
may expected to increase susceptibility of the vessels to regression factors. 6,7 Thus, 
a combined inhibition of the signalling pathway of both VEGF and PDGF could be 
more effective than only inhibition of the VEGF system for the treatment of CNV.6,8 
Conventional CNV therapy is based on the administration of corticosteroids. 
The antiangiogenic effect of steroids is thought to result from multiple anti-
inflammatory properties 9. However, corticosteroids are not always effective and can 
induce long-term side effects including the development of cataracts, glaucoma and 
increased risk of infection.2 The most commonly used anti-VEGF for off-label 
treatment of CNV is bevacizumab, a recombinant monoclonal antibody that directly 
acts against VEGF-A isoforms. However, experimental and clinical studies have 
shown that bevacizumab only partially reduces CNV.8,10-13 
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Tyrosine kinase inhibitors (TKIs) are small molecules that can inhibit the 
cascade of intracellular signal transduction stimulated by one or more tyrosine 
kinase receptors.14 These molecules have been well established as clinically useful 
drugs for the treatment of cancer.  
Axitinib is a potent synthetic molecule that stabilizes the kinase domain in an 
inactive conformation (TKI type II), blocking VEGF transduction signal.15. However, 
additional effects may occur on other targets including PDGFR- . 16 To the best of our 
knowledge, no work has yet to evaluate the antiangiogenic effects of topically 
administrated axitinib on corneal neovascularization. Thus, the purpose of the 
present study was to investigate the antiangiogenic capacity of topically 
administrated axitinib in a rabbit suture-induced CNV model.  
 
METHODS 
 
Axitinib (AG-013736) 
Axitinib is a potent small TKI derived from indazole (mw 386.47 Da) that has 
been demonstrated to be advantageous in a wide variety of tumours including 
melanomas, colorectal carcinomas, and tumours of the pancreas, thyroid, breast, 
and lung.17-19 At picomolar concentrations, it is a potent and highly selective inhibitor 
of VEGF tyrosine kinase receptors (VEGFR-1, VEGFR-2 and VEGFR-3). At nanomolar 
concentrations, it also inhibits the platelet-derived growth factor receptors α and β 
(PDGF-α and-β) 
Three topical concentrations of axitinib were selected based on the following 
rationale: a) 0.02 mg/ml axitinib: an axitinib concentration comparable to 
previous studies of 5 mg/ml bevacizumab to obtain comparable results. As a 
reference, we considered the in vitro results of the inhibition of human umbilical vein 
endothelial cell (HUVEC) proliferation induced by human VEGF165 acting on VEGFR-2. 
Drug concentrations for topical use were obtained from the product of its IC50 × 
222,222 because the used concentration of 5 mg/ml bevacizumab is approximately 
222,222 times its IC50; b) 0.35 mg/ml axitinib: an axitinib concentration 
comparable to 0.5 mg/ml sunitinib, as used in our previous studies.8,20 This 
concentration was calculated by considering the molecular weight of the drug to 
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employ the same number of moles; and c) 0.5 mg/ml axitinib: an equivalent dose 
to that used in previous studies of other TKIs, including sunitinib8,20 and 
pazopanib.21,22 
Axitinib was prepared from the active ingredient provided by LC laboratories 
(free base axitinib, LC Laboratories, Woburn, MA, USA) and dissolved in saline to the 
desired concentration. 
 
Experimental model and study groups 
A total of 48 New Zealand rabbits weighing 2.5 to 3 kg were randomly 
assigned to 4 groups (12 rabbits per group) corresponding to each of the selected 
drugs: Group 1 (control group) saline; group 2: axitinib 0.02 mg/ml; group 3: 
axitinib 0.35 mg/ml; and group 4: axitinib 0.5 mg/ml. 
A corneal neovascularization model was induced in the right eye of each 
rabbit with a triangular pattern based on the placement of five 8/0 interrupted blue 
virgin silk sutures suture (LorcaMarin SA, Murcia, Spain) at midstromal depth in the 
upper cornea following a limbal-based triangular pattern23 (Figure 1 a).  
 
Figure 1: a) Suture technique used to induce corneal neovascularization in rabbits; 
b) measurement of the stimulus area represented by the surface covered by sutures 
(SCS) using image processing software. 
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Under anaesthesia, slit-lamp photographic control was performed to quantify 
the angiogenic stimulus surface (surface covered by sutures, SCS) on day 3 and the 
corneal neovascularization surface (CNVS) on day 14. 
The rabbits were sacrificed after two weeks, and the corneas were processed 
by enzymatic staining to analyse the vascular microdensity. Eight eyes were 
designated to analyse vascular morphology, and four eyes, for the 
anatomopathological study. 
The measurement and quantification of all experimental procedures were 
performed by an examiner blinded to all treatment groups. All procedures and 
experimentation with the animals were performed according to the ARVO 
(Association for Research in Vision and Ophthalmology) standards for animal 
handling. 
 
Measurement of the surface covered by sutures (SCS) and quantification 
of CNV surface (CNVS) 
Two calibrated colour photographs of each cornea were taken to measure the 
corneal SCS on day 3 of follow-up. The corneal photographs were captured at a 
magnification of ×10 using a FinePix S2Pro digital camera (Fuji Photo Film 
Corporation Limited, Tokyo, Japan) attached to a slit-lamp (SL-D7, Topcon 
Corporation, Tokyo, Japan). Image-Pro Plus V.6.0 software (Media Cybernetics 
Incorporated, Bethesda, Maryland, USA) designed for image processing and analysis 
was employed. 
 
On day 14, rabbit corneas were also evaluated by slit-lamp biomicroscopy to 
quantify the CNVS. Two colour and one red-free photographs were calibrated using 
a graduated ruler with a resolution of 0.5 mm. The mean value from all 3 
photographs was used. 
 
Vascular microdensity and anatomopathological studies 
Eight eyes from each group were allocated for assessments of vascular 
morphology and vascular microdensity. The corneas were sectioned to obtain a 
block of triangular tissue containing the area covered by the sutures and, therefore, 
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Figure 3: The corneal stroma area to be studied was calculated by adding the 
corneal stroma areas of the 2 sections of each zone. Based on the sum of the 
stromal areas, the vessels and vascular microdensity were analysed. 
 
This article is protected by copyright. All rights reserved.
A
cc
ep
te
d 
A
rti
cl
e
false po
techniq
The diame
sitives, st
ue can sta
ter of a ca
ructures u
in the nuc
pillary is a
nder 5 μm
lei of som
pproximat
 were exc
e cells tha
ely 5 to 10
luded, as N
t are likely
 μm. Ther
ADPH dia
 involved 
efore, to a
phorase 
in the 
 
void 
This article is protected by copyright. All rights reserved.
A
cc
ep
te
d 
A
rti
cl
e
inflammatory response, as well as individual nerve fibres of the sub-basal plexus 
whose diameters vary between 0.05 and 0.25 µm. 
Four eyes from each group were allocated to the anatomopathological study. 
These eyes were stained using haematoxylin-eosin to evaluate the structural 
changes of the sutures, inflammatory infiltration, the distribution of corneal blood 
vessels in the corneal stroma, etc. 
 
Statistical analysis 
Parametric statistical tests were performed after verifying a normal 
distribution of the data by the one-sample Kolmogorov-Smirnov procedure. 
Differences were considered statistically significant when p values were less than 
0.05. 
 
RESULTS 
 
Corneal neovascularization surface (CNVS) 
CNVS data for each group are shown in Table 1, expressed in terms of square mm 
and the percentage of neovascularized area to corneal SCS. 
 
TABLE 1. Corneal Neovascularization Surface After 14 Days of Treatment (Mean ± 
SD) 
 
Group 1  
Saline 
Group 2 
Axitinib 
0.02 
mg/ml 
Group 3 
Axitinib 
0.35 
mg/ml 
Group 4 
Axitinib 
0.5 
mg/ml 
1-Way 
ANOVA
Square mm 31.50 ± 7.47 
19.20 ± 
8.92 
8.83 ± 
3.92 
5.12 ± 
3.97 
P < 
.001 
Percentage of 
neovascularized area 
to corneal area 
covered by sutures 
115.00 ± 
22.55 
73.89 ± 
34.98 
31.90 ± 
13.59 
18.38 ± 
13.75 
P < 
.001 
Inhibition rate 0% 39.04% 71.96% 83.74%  
ANOVA = analysis of variance; SD = Standard deviation. 
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group 4 (p = 0.01). The CNVS in group 3 was higher than that in group 4, but the 
difference was not statistically significant (p = 0.172). At day 14, CNV was inhibited 
39.04% by axitinib 0.02 mg/ml, 71.96% by axitinib 0.35 mg/ml and 83.74% by 
axitinib 0.5 mg/ml compared to CNV in the control group.  
 
Vascular morphology 
Before the section of the corneal samples, microscopy of corneal tissue 
stained with NADPH diaphorase showed that the emerging pericorneal arteries in 
group 1 (saline) were represented by branched projections oriented towards the 
sutures (angiogenic stimulus). As the vascular tree branched out, the uniform gauge 
of the arteries diminished towards the distal region, forming arterioles and 
capillaries. In the most distal areas of this vascular plexus of small anastomosing 
channels were the immature vascular buds of the neovascularization front. The 
venous vessels from the venules were located in somewhat deeper planes, 
presenting a greater calibre and softer staining with respect to the arteries. The 
veins followed a more irregular and sinuous path into the pericorneal veins (Figure 6 
a). 
In the axitinib-treated groups, the response was in many cases limited to 
arborescent structures consisting of one or more branched vascular axes. The 
ramifications emitted by each vascular axis did not present a clear orientation 
towards the angiogenic stimulus, as in the control group. At the distal ends, the 
vessels exhibited characteristics of capillaries, with more anastomoses and small 
vascular sprouts (Figure 6 b and c). 
 
Figure 6: Microscopic photograph of the corneal neovascularization surface stained 
with NADPH diaphorase in an eye treated with saline. Arterial vessels exhibited 
darker staining, uniform gauge and straight pathways with some ramifications for 
angiogenic stimulation. Venous vessels were generally located in deeper planes with 
soft staining and greater sinuosity. 
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significant differences only between group 2 (axitinib 0.02 mg/ml) and group 4 (0.5 
mg/ml) in zone 2 (p = 0.02). 
Interestingly, the percentage of vascular area did not exceed 5% with respect 
to the sectioned corneal stroma area in any rabbit of any group. 
Figure 9 shows the average vessels/mm2 and percentage of vascular area in 
zone 1 and zone 2. 
 
Figure 9: Variation between zone 1 (close to the limbus) and zone 2 (distal to the 
limbus) of the mean area of cut vessels, the number of vessels/mm2 of stroma and 
the vascular microdensity in terms of stromal area percentage occupied by vessels. 
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downward gradient in the vascular response with greater distances of the stimulus 
from the limbus. 
 
Anatomopathological study 
Granulomatous inflammation, in which lymphocytes and macrophages were 
predominant, was observed in the control group. Granulomatous inflammation 
occurred when macrophages accumulated substances that could not be digested 
(virgin silk) and transformed into epithelioid cells, constituting granulomas. 
Epithelioid cells contain an oval nucleus and a large central nucleolus and are 
organized to form cell masses with minimal space between cells (Figure 10 a). 
Eyes treated with axitinib exhibited a reduced inflammatory reaction, fewer 
changes in the structure of the stroma in corneal sections with less tissue oedema 
and fewer blood vessels. In the proximal sutures, the inflammatory reaction 
manifested itself as smaller-sized and more delimited granulomas. However, at the 
distal sites, there was a minimal inflammatory reaction characterized by the absence 
of blood vessels (Figure 10 b). 
 
Figure 10: Histological section of rabbit cornea 14 days after surgery. (H & E × 
100): a) Intense inflammatory response in the control group (saline); b) minimal 
inflammatory reaction at a proximal point of a rabbit cornea treated with axitinib. A 
small granuloma was well delimited around the sutures.  
This article is protected by copyright. All rights reserved.
A
cc
ep
te
d 
A
rti
cl
e
 
This article is protected by copyright. All rights reserved.
A
cc
ep
te
d 
A
rti
cl
e
Ocular side effects 
The rabbits’ eyes did not show signs of conjunctival hyperaemia, corneal 
ulcers, or iris or lens abnormalities in any of the groups during the study follow-up. 
In some rabbits of each group, a slight cellular reaction in the anterior chamber (5-
10 cells/1x3 mm of beam) associated with the surgical procedure occurred, which 
was resolved in the following days without consequences. Examination of the fundus 
of the eye was also normal in all groups. 
 
DISCUSSION 
 
The activity of axitinib is related to the structure of the molecule and the 
spectrum of inhibition of the kinase. At low concentrations, axitinib appears to be 
considerably selective for VEGF receptors (VEGFR-1, VEGFR-2 and VEGFR-3). The 
effects of axitinib result from its binding to the kinase domain of VEGF receptors, 
stabilizing it in an inactive conformation and, consequently, inhibiting VEGF 
transduction signal.19 
Selective VEGF-A blockade, as with monoclonal antibodies, neutralizes the 
signal initiated by the growth factor. However, there is a range of VEGF subtypes, all 
of which play a role in signalling the three kinds of VEGF receptors. Because of the 
central role of VEGFR kinase activity, a small molecule such as axitinib that blocks 
VEGFR-1, -2 and -3 could provide a complete approach for blocking VEGF signalling, 
which would include inhibition of hemangiogenesis and lymphangiogenesis. 
PDGF-B signalling, through PDGFR-β receptors, regulates the recruitment of 
mural cells into the growing vascular endothelial tube. Mural cells (pericytes and 
smooth muscle cells) are necessary for normal vessel function and stability. 
Endothelial vascular sprouts secrete PDGF-B, and by binding to PDGFR-β receptors 
expressed by pericytes, PDGF-B facilitates the proliferation, differentiation and 
migration of the same pericytes to stabilize new blood vessels.24 
In 2010, we published the results of an experimental rabbit cornea study 
comparing sunitinib (anti-VEGF and anti-PDGF) with bevacizumab (monoclonal anti-
VEGF antibody). We demonstrated that sunitinib topically inhibits CNV by 82.3% and 
that topical administration of sunitinib was 3 times more effective than topical 
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bevacizumab after 14 days of treatment.8 The findings suggested that simultaneous 
blockade of the VEGF and PDGF systems is more effective in inhibiting CNV than 
only blockade of the VEGF system.8 This fact is of great relevance, since without the 
support of pericytes and VEGF signalling, apoptosis of the endothelial cell occurs.25-28 
In a murine model of laser-induced choroidal neovascularization, Kang et al 
demonstrated that oral administration of axitinib at 5 mg/kg results in regression of 
established neovascularization29. Consistent with these findings, Giddabasappa et al 
showed continuous administration of axitinib at a lower dose (0.875 mg/day) for 7 
days significantly inhibited vascular leakage and neovascularization in a rat model of 
laser-induced choroidal neovascularization.30 This ability of axitinib may be a 
consequence of its activity as a multiple receptor tyrosine kinase inhibitor. Therefore, 
axitinib, which targets several angiogenic growth factor pathways, including VEGF 
receptor 2 and PDGF receptor pathways, may be a potent promoter of established 
choroidal neovascularization regression.29,30 
 
To our knowledge, it is the first study to show the antiangiogenic activity of 
topical axitinib in a model of ocular neovascularization in rabbits. After 14 days of 
topical treatment with axitinib at different concentrations (groups 2, 3 and 4), 
significant inhibition of CNVS was observed compared with the control group (group 
1, saline). Axitinib at 0.02 mg/ml (group 2) inhibited the CNVS by 39.04%, and 
axitinib at 0.35 mg/ml (group 3) caused significant and intense inhibition by 71.96% 
of the CNVS. The inhibitory response induced by 0.5 mg/ml axitinib (group 4) was 
greater, inhibiting neovascularization by 83.74% with respect to the control group, 
although no significant differences in inhibition were found between groups 3 and 4. 
However, 0.35 mg/ml axitinib (group 3) and 0.5 mg/ml axitinib (group 4) were 
significantly more effective than group 2 (0.02 mg/ml) in terms of inhibition of 
CNVS. 
Comparing the results of this study with those obtained in previous trials of 
sunitinib using the same methodology, 0.35 mg/ml axitinib and 0.5 mg/ml axitinib 
did not induce significant differences in the inhibition of CNVS compared with 0.5 
mg/ml sunitinib (data not shown).8,20 
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It is unclear whether other inhibitory activities of axitinib contribute to its high 
level of efficacy, although there is some evidence that a simultaneous blockade of 
PDGF and VEGF-A could be superior to blockade of either alone. In this regard, 
agents that inhibit multiple angiogenic pathways would be more desirable for 
improving therapeutic approaches. 
In a pathological clinical study in corneal buttons, Cursiefen and coauthors 
observed that more than 80% of vessels were covered by pericytes at two weeks 
after the onset of CNV.31 Therefore, combined treatment against endothelial cells 
and pericytes is necessary to enhance treatment against new blood vessels in an 
advanced stage of maturation. Pericytes, recruited by the vessels through the action 
of PDGF, join with the vessel during formation, thus stabilizing it. In this state, 
endothelial cells become less dependent on VEGF. In addition to the paracrine 
process, cell-cell contact enhances the survival of vascular endothelial cells.32,33 
Thus, in an advanced stage of maturation, the vessels are restrictive towards anti-
VEGF therapy. Attenuation of pericytes caused by PDGF blockade may potentiate the 
antiangiogenic effect of VEGF receptor inhibitors.34 Therefore, more attention should 
be paid to pericytes and their interactions with endothelial cells to better understand 
the full potential of antiangiogenic therapy. 
In relation to the vascular microdensity, a reduction in the number of vessels 
and in the percentage of the vascular area with respect to the stroma was observed 
in the groups treated with axitinib compared to the control group. Among the 
different concentrations of axitinib, a significant difference was only found between 
the concentrations of 0.02 mg/ml axitinib and 0.5 mg/ml axitinib, with 0.02 mg/ml 
axitinib inducing a significantly lower effect. 
According to the morphological findings of the vascular tree in the groups 
treated with axitinib (groups 2-4), the vascular axes consisted of a small-calibre 
central artery with short branches without a definite orientation, suggest that the 
molecular and biological processes associated with the VEGF and/or PDGF system 
could be relevant in the remodelling of neoformed vessels. 
Compared with the control group, histological corneal sections of the axitinib 
groups generally showed lower inflammation with delimited granulomas around the 
proximal sutures with a more homogeneous and localized distribution of 
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lymphoplasmacytic infiltrate, epithelial cells, and macrophages. In the distal sutures 
of the high-concentration axitinib groups, almost no inflammatory reaction was 
observed. These characteristics of the immune response could be explained by 
potent inhibition of blood and lymphatic vessels, allowing access of inflammatory 
cells to the sutures only by diffusion through the stroma from preexisting limbic 
vessels and marginal blood vessels. In fact, TKIs, by blocking VEGF receptors, 
reduce the recruitment of lymphatic precursor cells and antigen-presenting cells 
(APCs) and suppress the proliferation of vascular endothelial cells.35 
The safety of topical axitinib for the treatment of CNV was also determined in 
this study by evaluating ocular and systemic adverse effects. At the different doses 
studied topical axitinib was well tolerated after 14 days of treatment, and no adverse 
effects were observed on ocular structures. 
The adverse effects profile of axitinib that occurs with continuous systemic 
administration appears to be comparable with the adverse effect profile that occurs 
for administration of systemic anti-VEGF medications. The most common of the 
adverse effects produced by systemic axitinib is fatigue caused by hypothyroidism.18 
Other related effects are hypertension, anorexia, hoarseness and nausea.36 
However, adverse effects are generally well managed with dose modification and 
supportive treatment.17,18,36 In treatments to suppress VEGF for neovascular 
diseases of the eye, the following factors must be considered. In the cornea, VEGF 
appears to have a neurotrophic effect. Thus, caution should also be taken when 
applying anti-VEGF treatments in the presence of epithelial defects or in situations 
where healing of a corneal wound occurs.37 On the other hand, in a murine model 
with a PDGF-B deficiency, the presence of focal vascular retinopathy accompanied 
by a loss of mural cells (pericytes) of the vessels has been described, and such mice 
develop a pathology similar to diabetic retinopathy.25,38 
In previous experimental studies of sunitinib in rabbits, yellowish staining was 
observed in the iris of the eyes of all rabbits, which disappeared within a few days 
after discontinuation of treatment. This staining was caused by deposition of 
sunitinib on the surface of the iris because the agent in suspension has a golden-
yellow colour. The deposition of sunitinib on the surface of the iris was largely 
relevant, because the yellow colour functioned as a tracer indicating that the 
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molecule was able to reach the anterior chamber after topical application. This 
finding could be of great clinical utility for the treatment of intraocular neovascular 
diseases.8,39 
However, it is true that, in clinical practice, an undesired side effects must be 
considered, especially for prolonged or chronic treatments. In our study, we did not 
observe any adverse side effects with axitinib treatment because it is white, and 
after dilution with saline serum, becomes colourless. 
In summary, a novel, topically administered, tyrosine kinase receptor 
inhibitor, axitinib, significantly and extensively inhibited corneal neovascularization in 
rabbit eyes. The high capacity of axitinib to block neovascularization in the cornea 
could be a consequence of its multitargeting activity, inhibiting both VEGF and PDGF. 
In addition, by blocking VEGFR-3, axitinib could inhibit corneal lymphangiogenesis 
and was able to promote the survival of corneal grafts after corneal transplant. 
Axitinib, at the doses and duration used in the study, is safe and well 
tolerated. However, further studies are needed to define the possible side effects 
and toxicity of this drug when used in the eye for an extended period of time. 
Additional studies are needed to determine its mechanisms of action, optimal doses, 
and side effects. In this context, it is mandatory to carry out randomized controlled 
clinical trials to establish the effectiveness and safety of the treatment regimens of 
axitinib for future applications as a therapeutic alternative for treating ocular 
neovascular pathology. 
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